Zai Lab (ZLAB) Citi’s 2026 Virtual Oncology Leadership Summit summary

Strategic transformation and pipeline overview

• Transitioning from a China-focused business to a global enterprise, leveraging a dual engine of local and global R&D and commercialization.

• Lead product Zoci (DLL3 ADC) is in phase III, with a robust global pipeline including protein therapeutics, ADCs, immunocytokines, and T cell engagers.

• Launches of COBENFY and TIVDAK planned this year, with a regulatory filing for tumor treating fields in pancreatic cancer.

• Global studies are enrolling across the US, Europe, China, Japan, Korea, and Turkey.

• Plans to file at least one IND annually and expand through business development.

Lead asset: Zoci (DLL3 ADC) clinical development

• Phase III study in small cell lung cancer, following strong phase I/II data showing a 68% response rate and over 6 months durability.

• Dose of 1.6 mg/kg selected for optimal efficacy and safety, with low Grade 3 toxicity and no discontinuations.

• High activity in brain metastases, with 80% response after first or second dose.

• Accelerated approval targeted based on overall response rate, with interim analysis expected around March next year and potential filing in 2027.

• Frontline and neuroendocrine carcinoma studies planned to start this year, with combinations under evaluation.

Competitive landscape and innovation

• Zoci positioned as a safe, effective ADC with advantages over competitors in dose, safety, and combinability.

• ADCs and T cell engagers seen as complementary, with ADCs effective in bulky disease and lower target expression.

• Other DLL3 ADCs are in development, but Zoci is at least a year ahead of the most advanced competitor.